Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-44. (Canceled)

45. (Previously presented) A method for reducing anxiety in a subject in need thereof by increasing ion flow through KCNQ potassium channels in a cell, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound, wherein said compound has the formula:



wherein

Ar^1 is a member selected from the group consisting of phenyl, substituted phenyl, 2-indolyl, substituted 2-indolyl, benzofuranyl, substituted benzofuranyl, furanyl, substituted furanyl, thienyl, substituted thienyl, isothiazolyl, substituted isothiazolyl, pyrazolyl and substituted pyrazolyl;

wherein the substituent(s) for the Ar^1 member are selected from the group consisting of halogen, unsubstituted alkyl, unsubstituted halo(C_1-C_4)alkyl, unsubstituted (C_1-C_4)alkoxy, unsubstituted halo(C_1-C_4)alkoxy, nitro, cyano, -NHC(O)R^7, -NHR^7, and unsubstituted phenyl;

wherein R^7 is a member selected from hydrogen, unsubstituted (C_1-C_8)alkyl, unsubstituted cycloalkyl, unsubstituted heteroalkyl, unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted heteroaryl, and unsubstituted aryl(C_1-C_4)alkyl, or R^7 can be combined with the nitrogen to which it is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices.

Ar^2 is substituted or unsubstituted pyridyl;

wherein the substituent(s) for the Ar^2 member are selected from the group consisting of halogen, unsubstituted C_1-C_4 alkyl, $-CF_3$, $-OCH_3$ and $-OCF_3$;

X is a member selected from the group consisting of O and S.

46. (Original) The method of claim 45, wherein the anxiety is caused by panic disorder, generalized anxiety disorder, or stress disorder.

47. (Original) The method of claim 46, wherein the stress disorder is acute stress disorder or post-traumatic stress disorder.

48. (Original) The method of claim 45, wherein the subject is a human.

49. (Original) The method of claim 45, wherein the KCNQ channel is a heteromeric channel.

50. (Original) The method of claim 45, wherein the KCNQ channel is a homomeric channel.

51. (Previously Presented) The method of claim 49, wherein the heteromeric KCNQ channel comprises a KCNQ2 polypeptide subunit.

52. (Previously Presented) The method of claim 49, wherein the heteromeric KCNQ channel comprises a KCNQ3 polypeptide subunit.

53. (Original) The method of claim 52, wherein the KCNQ channel is KCNQ2/3.

54. (Original) The method of claim 45, wherein the potassium channel-opening amount is 0.1 mg/kg to 200 mg/kg.

55. (Original) The method of claim 54, wherein the potassium channel-opening amount is 10 mg/kg to 100 mg/kg.

56. (Original) The method of claim 45, wherein the composition is administered orally.

57. (Original) The method of claim 45, wherein the composition is administered by injection.

58. - 59. (Canceled)

60. (Previously Presented) The method according to claim 45, wherein Ar^1 is substituted phenyl, substituted or unsubstituted 2-indolyl, or substituted or unsubstituted 2-thienyl.

61. (Previously Presented) The method according to claim 45, wherein X is O.

62. (Previously presented) The method according to claim 60, wherein the Ar^1 substituents are selected from the group consisting of halogen, unsubstituted alkyl, unsubstituted halo(C_1-C_4)alkyl, nitro, and cyano.

63. - 64. (Canceled)

65. (Previously presented) The method according to claim 62, wherein Ar^2 is unsubstituted pyridyl.

66. (Original) The method according to claim 65, wherein Ar^2 is selected from the group consisting of 6-methyl-3-pyridyl and 2-chloro-5-pyridyl.

67. (Original) The method according to claim 65, wherein Ar^1 is substituted phenyl.

68. (Original) The method according to claim 67, said compound having the formula:



wherein,

Y is a member selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_4 substituted alkyl, -OCH_3 and -OCF_3, and R^5 and R^6 are members independently selected from the group consisting of H, halogen, alkyl, halo(C_1-C_4)alkyl, nitro, cyano and phenyl, with the proviso that both R^5 and R^6 are not H.

69. (Original) The method according to claim 68, wherein R^5 and R^6 are members independently selected from the group consisting of H, F, and Cl, with the proviso that both R^5 and R^6 are not H.

70. - 82.(Canceled)

83. (Previously Presented) The method according to claim 45, wherein said compound has the formula: